Two large studies of people switching to tenofovir-sparing regimens presented at the 20th European AIDS Conference (EACS 2025) in Paris show that hepatitis B reactivation is a rare event after the hepatitis B-suppressive drug is removed.
Hepatitis…
Hepatitis B reactivation is rare after switching from tenofovir, two European studies show
